news
Oct 25, 2016
Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV
Boston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...
Read More...
Oct 18, 2016
Merck launches Biosimilars, ABITEC announces extension, First human clinical trial, FDA awards 2grants, Corden Pharma Expands, Juniper Pharma Services Offers
Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community Merck has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, conc...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
